Compass Therapeutics Inc. (CMPX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
80 GUEST STREET BOSTON, MA 02135 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 152,461,000 | 163,703,000 | 168,752,000 | 175,000,000 | 186,609,000 | 120,602,000 | |||
| Cash and cash equivalents | 24,228,000 | 30,426,000 | 19,278,000 | 27,027,000 | 34,946,000 | 16,481,000 | |||
| Short-term investments | 128,233,000 | 133,277,000 | 149,474,000 | 148,143,000 | 151,663,000 | 104,121,000 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | (170,000) | ||||||||
| Other undisclosed current assets | 1,420,000 | 2,881,000 | 6,520,000 | 8,602,000 | 8,182,000 | 1,952,000 | |||
| Total current assets: | 153,881,000 | 166,584,000 | 175,272,000 | 183,602,000 | 194,791,000 | 122,554,000 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,776,000 | 2,083,000 | 2,385,000 | 2,680,000 | 2,967,000 | 3,256,000 | |||
| Property, plant and equipment | 898,000 | 1,051,000 | 1,204,000 | 1,373,000 | 1,567,000 | 1,708,000 | |||
| Other noncurrent assets | 320,000 | 320,000 | 320,000 | 320,000 | 320,000 | 320,000 | |||
| Total noncurrent assets: | 2,994,000 | 3,454,000 | 3,909,000 | 4,373,000 | 4,854,000 | 5,284,000 | |||
| TOTAL ASSETS: | 156,875,000 | 170,038,000 | 179,181,000 | 187,975,000 | 199,645,000 | 127,838,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,604,000 | 7,950,000 | 8,551,000 | 10,068,000 | 15,072,000 | 9,721,000 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1,218,000 | ||
| Accounts payable | 4,090,000 | 2,306,000 | 724,000 | 1,125,000 | 3,382,000 | 2,761,000 | |||
| Accrued liabilities | 2,514,000 | 5,644,000 | 7,827,000 | 8,943,000 | 11,690,000 | 5,742,000 | |||
| Other undisclosed current liabilities | 1,197,000 | 1,174,000 | 1,147,000 | 1,122,000 | 1,097,000 | (143,000) | |||
| Total current liabilities: | 7,801,000 | 9,124,000 | 9,698,000 | 11,190,000 | 16,169,000 | 9,578,000 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 2,144,000 | ||||||||
| Liabilities, other than long-term debt | 536,000 | 869,000 | 1,197,000 | 1,520,000 | 1,838,000 | ||||
| Operating lease, liability | 536,000 | 869,000 | 1,197,000 | 1,520,000 | 1,838,000 | 2,144,000 | |||
| Other undisclosed noncurrent liabilities | (2,144,000) | ||||||||
| Total noncurrent liabilities: | 536,000 | 869,000 | 1,197,000 | 1,520,000 | 1,838,000 | 2,144,000 | |||
| Total liabilities: | 8,337,000 | 9,993,000 | 10,895,000 | 12,710,000 | 18,007,000 | 11,722,000 | |||
| Equity | |||||||||
| Equity, attributable to parent | 148,538,000 | 160,045,000 | 168,286,000 | 175,265,000 | 181,638,000 | 116,116,000 | |||
| Common stock | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 10,000 | |||
| Additional paid in capital | 463,796,000 | 462,355,000 | 460,709,000 | 456,049,000 | 454,741,000 | 377,967,000 | |||
| Accumulated other comprehensive income (loss) | 37,000 | (430,000) | (507,000) | (146,000) | (302,000) | (641,000) | |||
| Accumulated deficit | (315,308,000) | (301,893,000) | (291,929,000) | (280,651,000) | (272,814,000) | (261,220,000) | |||
| Total equity: | 148,538,000 | 160,045,000 | 168,286,000 | 175,265,000 | 181,638,000 | 116,116,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 156,875,000 | 170,038,000 | 179,181,000 | 187,975,000 | 199,645,000 | 127,838,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (15,393,000) | (11,926,000) | (13,337,000) | (9,711,000) | (12,888,000) | (12,598,000) | ||
| Operating loss: | (15,393,000) | (11,926,000) | (13,337,000) | (9,711,000) | (12,888,000) | (12,598,000) | ||
| Nonoperating income (Other Nonoperating income) | 1,978,000 | 1,962,000 | 2,059,000 | 1,874,000 | 1,294,000 | 623,000 | ||
| Loss from continuing operations: | (13,415,000) | (9,964,000) | (11,278,000) | (7,837,000) | (11,594,000) | (11,975,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | (11,975,000) | |
| Net loss available to common stockholders, diluted: | (13,415,000) | (9,964,000) | (11,278,000) | (7,837,000) | (11,594,000) | (11,975,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (13,415,000) | (9,964,000) | (11,278,000) | (7,837,000) | (11,594,000) | (11,975,000) | ||
| Comprehensive loss: | (13,415,000) | (9,964,000) | (11,278,000) | (7,837,000) | (11,594,000) | (11,975,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 467,000 | 77,000 | (361,000) | 156,000 | 339,000 | (129,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (12,948,000) | (9,887,000) | (11,639,000) | (7,681,000) | (11,255,000) | (12,104,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.